Intellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($1.49), $0.20 worse than the analyst estimate of ($1.29). Revenue for the quarter came in at $13.27 million versus the consensus estimate of $11.43 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.